# Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)

> **NCT05016609** · PHASE4 · UNKNOWN · sponsor: **Macfarlane Burnet Institute for Medical Research and Public Health Ltd** · enrollment: 1800 (estimated)

## Conditions studied

- Hepatitis C

## Interventions

- **DEVICE:** OraQuick HCV Antibody test (OraSure Technologies, Inc)
- **DEVICE:** Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)
- **DRUG:** Sofosbuvir/Velpatasvir (Gilead)

## Key facts

- **NCT ID:** NCT05016609
- **Lead sponsor:** Macfarlane Burnet Institute for Medical Research and Public Health Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-09
- **Primary completion:** 2024-04
- **Final completion:** 2024-06
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05016609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05016609, "Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05016609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*